Amifostine reduces inflammation and protects against 5-fluorouracil-induced oral mucositis and hyposalivation
Authors:
- S.C.M. BarbosaSBS.C.M. Barbosa
- V.B.M. PereiraVPV.B.M. Pereira
- D.V.T. WongD.V.T. Wong
- A.P.M. SantanaASA.P.M. Santana
- L.T. LucettiLLL.T. Lucetti
- L.L. CarvalhoLCL.L. Carvalho
- C.R.N. BarbosaCBC.R.N. Barbosa
- R.B. CalladoRCR.B. Callado
- C.A.A. SilvaCSC.A.A. Silva
- G.A.C. BritoGBG.A.C. Brito
- N.M.N. AlencarNAN.M.N. Alencar
Open Access
- 1 January 2019
- journal article
- research article
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Medical and Biological Research
- Vol. 52 (3) , e8251
Abstract
Oral mucositis (OM) is a common and dose-limiting side effect of cancer treatment, including 5-fluorouracil (5-FU) and radiotherapy. The efficacy of the therapeutic measures to prevent OM is limited and disease prevention is not fully observable. Amifostine is a cytoprotective agent with a described anti-inflammatory potential. It is clinically used to reduce radiotherapy and chemotherapy-associated xerostomia. This study investigated the protective effect of amifostine on an experimental model of OM. Hamsters were divided into six groups: saline control group (5 mL/kg), mechanical trauma (scratches) of the right cheek pouch; 5-FU (60 and 40 mg/kg, ip, respectively, administered on days 1 and 2); amifostine (12.5, 25, or 50 mg/kg) + 5-FU + scratches. Salivation rate was assessed and the animals were euthanized on day 10 for the analysis of macroscopic and microscopic injury by scores. Tissue samples were harvested for the measurement of neutrophil infiltration and detection of inflammatory markers by ELISA and immunohistochemistry. 5-FU induced pronounced hyposalivation, which was prevented by amifostine (Pvs 5-FU group). Amifostine reduced inflammation and protected against 5-FU-associated oral mucositis and hyposalivation.Keywords
This publication has 31 references indexed in Scilit:
- Systematic review of amifostine for the management of oral mucositis in cancer patientsSupportive Care in Cancer, 2012
- New thoughts on the initiation of mucositisOral Diseases, 2010
- Role of Capsaicin-Sensitive Primary Afferent Neurons and Non-protein Sulphydryl Groups on Gastroprotective Effect of Amifostine Against Ethanol-Induced Gastric Damage in RatsDigestive Diseases and Sciences, 2010
- Management of oral and gastrointestinal mucositis: ESMO Clinical RecommendationsAnnals of Oncology, 2009
- Amifostine (Wr-2721) Prevents Indomethacin-Induced Gastric Damage in Rats: Role of Non-Protein Sulfhydryl Groups and Leukocyte AdherenceDigestive Diseases and Sciences, 2006
- Amifostine in the management of radiation-induced and chemo-induced mucositisSupportive Care in Cancer, 2006
- Effects of the tumour necrosis factor‐α inhibitors pentoxifylline and thalidomide in short‐term experimental oral mucositis in hamstersEuropean Journal of Oral Sciences, 2005
- Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositisCancer, 2004
- An animal model for mucositis induced by cancer chemotherapyOral Surgery, Oral Medicine, Oral Pathology, 1990
- Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures.Journal of Histochemistry & Cytochemistry, 1981